What were the key compensation changes for Gilead's executives reported in this filing?

This filing primarily details the setting of 2011 base salaries and the determination of 2010 bonus awards for named executive officers. It also outlines the granting of new stock options and performance share awards for 2011, with terms tied to future company performance and executive service.

How is the payout of performance shares determined?

The payout of performance shares is contingent on Gilead's performance over a three-year period (2011-2013) measured against a peer group index. Specifically, it depends on the company's Total Shareholder Return (TSR) and revenue growth relative to this index. The actual number of shares received can range from 0% to 200% of the target award, based on defined percentile rankings.

What happens to the performance shares if an executive leaves the company or if there is a change in control?

Generally, performance shares are forfeited if an executive's service terminates before the end of the performance period. However, exceptions exist for death, disability, or retirement under specific conditions, where a prorated portion may be awarded. In the event of a change in control, performance shares can vest immediately at 100% or more, depending on the timing and performance metrics calculated over an abbreviated period.

What is the significance of the stock option grants and their vesting schedule?

The stock options grant executives the right to purchase Gilead shares at a fixed price ($38.17) and are intended to incentivize stock price appreciation. The vesting schedule, which spreads over four years with initial vesting after one year, encourages long-term commitment to the company.

GILD 8-K: Leadership Changes

Summary

Gilead Sciences, Inc. (GILD) filed an 8-K on January 25, 2011, reporting on executive compensation arrangements for fiscal year 2011. The Compensation Committee of the Board of Directors set 2011 base salaries and determined 2010 bonus awards for its named executive officers. Additionally, the company granted stock options and performance share awards under its 2004 Equity Incentive Plan, with vesting and payout contingent on continued service and company performance metrics. These arrangements reflect management's compensation structure and incentivize future performance aligned with shareholder interests.

Key Highlights

12011 Base Salaries and 2010 Bonuses Set for Executive Officers: The report details the base salaries for 2011 and bonus awards for 2010 for key executives, including the CEO, President, CFO, and heads of R&D and Commercial Operations.
22011 Stock Option Grants: Executive officers received stock options with an exercise price of $38.17, vesting over four years with 25% on the first anniversary.
3Performance Share Awards Granted: In addition to options, executives were granted performance shares tied to the company's Total Shareholder Return (TSR) and revenue growth relative to a peer group index over a three-year period (January 1, 2011 - December 31, 2013).
4Performance Share Payout Structure: The number of performance shares that convert to actual stock can range from 0% to 200% of the granted amount, based on percentile rankings in TSR and revenue growth compared to the NYSE Arca Biotech and Pharmaceutical Indexes.
5Maximum Payout Criteria: A 200% payout is achievable if Gilead's TSR and revenue growth are both at or above the 80th percentile of the peer group index.
6Minimum Payout Criteria: No shares will be awarded if Gilead's TSR and revenue growth are both below the 20th percentile of the peer group index.
7Change in Control Provisions: In the event of a change in control, performance shares may immediately vest at 100% of the granted number, or a potentially higher amount if the change in control occurs after one year and TSR/revenue growth are measured over an abbreviated period.

GILEAD SCIENCES, INC. 8-K Report, Executive Changes (Jan 25, 2011)

Summary

Key Highlights

Frequently Asked Questions